RNAZ
Transcode Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.93M
P/E Ratio
—
EPS
$-3.71
Beta
1.40
52W High
$20.99
52W Low
$5.56
50-Day MA
$8.18
200-Day MA
$9.60
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.12M |
| Operating Margin | 0.00% |
| Return on Equity | -46.30% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.71 |
| Price-to-Book | 4.58 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 950,300 |
| Float | 835,400 |
| % Insiders | 9.22% |
| % Institutions | 8.62% |
Historical Volatility
HV 10-Day
49.60%
HV 20-Day
42.98%
HV 30-Day
45.05%
HV 60-Day
45.60%
HV Rank
7.5%
Volatility is currently expanding
More HEALTHCARE Stocks
Data last updated: 5/25/2026